Member Info for shatter

Obfuscate….great word..

Pie boy… no, you will get the cash in a day or two that makes up for the shares so you will be no worse off.

Bought a few more at 396 ( bit slow off the mark)on the Halifax site. Platform still a tad messed up but transaction went through okay.

It’s done and dusted now. The sp will find its new level and the b shares can eventually be reinvested or not. The sp is bound to rise with the Ordinary Divi payment next week.
I’m hoping it doesn’t go too far either way over the coming weeks to enable reinvestment. G.l all whatever you decide..

Maybe just give it a week or two!

Worth averaging down? Surely there must be good news re a contract or two in the next few week that should lift the sp again.

As you say it’s a bad day at the office all round. Long term holder so will sit tight, roll the dice and see what happens. We will have a reasonable idea where this is going in a week or two. Sure it’s only money….

Is it better that the share price is dropping pre - consolidation?

Director buys should perhaps have been renamed desperation buys - the feeling that you have when you are in such a bad situation that you are willing to take risks in order to change it:
Well… the director buys have really worked ! As for directors selling major holdings that would be the kiss of death so they are hurting like everyone else. Other posters are hoping , if not praying, for a buyout at this lowly price. Need a contract or two to stop the rot.

Hi Kern,
Yeah, it doesn’t look very temporary, unfortunately.

Let’s hope it’s only temporary. Oxb are going to need a miracle to stop this decline ! The vaccine contract has got to be finished whether Oxb want to admit it or not.

As usual Oxb is short on detail -The Company has fully drawn down the $85m Short Term Loan Facility with Oaktree which has been used to temporarily bridge fund the Acquisition and the $50m cash injection into Oxford Biomedica Solutions. Millions in interest on this very expensive loan/ debt. No mention of cash burn and how long before the coffers are empty ! Judging by the sp the market is not impressed .

Thanks for all your comments . It seems I mistakenly thought that that the proceeds from the capital return, being cash from the sale of shares, was no longer in the Isa after the sale but that is not the case. Happy days, thanks all.

Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby, Chief Business & Corporate Development Officer of the Group, exercised 8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the resulting ordinary shares at 539.0p per share.

Once the shares are sold I was led to believe that they are no longer in the isa wrapper. You can transfer Isa’s but the second they are sold any proceeds lose their Isa status.

Agree with ftsee. It won’t be reinvested. Held back the Isa for this which is a bit annoying…

Reinvested tomorrow morning. A longtime hold..

Morning Kern,
Don’t know about sound judgement ! It’s difficult to know what to do at the moment. As we know from experience this can be very volatile, a slow burner and took what seemed like a lifetime to reach its previous highs. The Astra contract must be mostly priced in so it’s a case of can they continue to pay their bills and can they turn Homology to profit ?
I am not so sure that we won’t see another fund raising in the coming months if they don’t secure some decent contracts but who knows what is in the pipeline? Oxb certainly won’t give us any hints.. sorry can’t be any help..

Hi Kern
It does look like we have been kept in the dark concerning the Astra contract. No mention of when they stopped manufacture of the vaccine ? Why they went ahead with the Homology purchase is beyond me and seemingly the CEO and Diggle amongst others.
I would have considered buying back in at some point if the conditions were right but I don’t trust the directors. There appears to be a worldwide over supply of vaccines ( which is great) but not good news for Oxb and another contract. It’s supply and demand and there doesn’t appear to be a demand at the moment.
I hope they can pull a rabbit out of the hat and turn Homology around as cash burn is a real issue ‘again’. Just like the good old days..

From Investors Chronicle…
Covid-19 proved to be a boon for certain companies, but pandemic-linked benefits are beginning to dissipate. Oxford BioMedica’s (OXB) share price has been in retreat since the beginning of November. That trend was maintained on results day as the vaccine manufacturer guided for reduced revenue in 2022 due to a pause in vaccine manufacturing activity. Much depends on the outcome of negotiations with AstraZeneca (AZN) over a possible extension to a supply agreement in relation to its Covid-19 vaccine.
Put simply, the trajectory of the share price remains intertwined with the clinical relationship with AstraZeneca. It’s no surprise, therefore, that short positions on the stock increased throughout March.
Is the sp sitting in limbo waiting for news from Astra? I have a notion that this “pause” is permanent . There must be a certain amount of this built into the sp at present but I wouldn’t rule out a further drop if Oxb ever get round to telling its shareholders that talks with Astra have come to nowt if that is the case. It unfortunately took Oxb months to tell us about the “pause”.